Bumetanide considered effective in the treatment of genetic Alzheimer's by the end of 2026?
Gesundheit & MedizinOne-Off2Mon
FutuurVerfügbarkeit prüfenVerifizierte AuflösungsdatenAktuelle implizite Wahrscheinlichkeit
Nein 93%
Nein 93%Marktqualitat
31 / 100
Niedrige Qualität24h-Volumen
—
Liquidität
230 €
Niedrige LiquiditätTrader
9
Kommentare
1
Marktdaten
Aktualisiert vor 1 Minute
Trends
Regeln
Drug repositioning is a common technique in research, where drugs that have already been approved to treat a certain disease are used to treat different diseases.
- By cross-referencing information from various sources, scientists in the United States have arrived at a drug that might be repositioned to treat Alzheimer's disease in patients with genetic mutations that increase the risk of developing the disease.
- According to their studies, Bumetanide - a diuretic drug - managed to reduce learning deficits in mice, and showed positive effects in human neurons in vitro.
- The next step was to analyze the medical records of more than 5 million adult patients, which led to the observation that the development of Alzheimer's disease was lower among those who made use of the diuretic drug.
- Despite the encouraging news, more tests are still needed to validate such a hypothesis.
- The next step for researchers will be to conduct randomized clinical trials to demonstrate the efficacy of bumetanide against genetic Alzheimer's disease.
